Phase I and Pharmacokinetic Study of the Ribonucleotide Reductase Inhibitor, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, Administered by 96-Hour Intravenous Continuous Infusion
Wadler, S., Makower, D., Clairmont, C., Lambert, P., Fehn, K., Sznol, M.Volume:
22
Language:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/JCO.2004.07.158
Date:
May, 2004
File:
PDF, 235 KB
english, 2004